• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Khalid Shah, MS, PhD


  • Kuruppu D, Brownell AL, Shah K, Mahmood U, Tanabe KK.Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.Cancer Res. 2014 May 29.
  • Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K.Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.Journal of the National Cancer Institute. 2014 Jun;106(6).
  • Du W, Uslar L, Sevala S, Shah K.Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors.PLoS ONE. 2014;9(4):e95490.
  • Zhu Y, Shah K.Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.Cancer Biol Ther. 2014 Mar 21;15(6).
  • Stuckey DW, Shah K.TRAIL on trial: preclinical advances in cancer therapy.Trends Mol Med. 2013 Nov;19(11):685-94.
  • Shah K.Encapsulated stem cells for cancer therapy.Biomatter. 2013 Jan 1;3(1).
  • Guo Y, Yuan H, Cho H, Kuruppu D, Jokivarsi K, Agarwal A, Shah K, Josephson L.High efficiency diffusion molecular retention tumor targeting.PLoS ONE. 2013;8(3):e58290.
  • Martinez-Quintanilla J, Bhere D, Heidari P, He D, Mahmood U, Shah K.In vivo Imaging of the Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors.Stem Cells. 2013 Feb 6.
  • Hingtgen S, Figueiredo JL, Farrar C, Duebgen M, Martinez-Quintanilla J, Bhere D, Shah K.Real-time multi-modality imaging of glioblastoma tumor resection and recurrence.J. Neurooncol. 2013 Jan;111(2):153-61.
  • Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.Mol Ther. 2013 Jan;21(1):68-77.
  • Nesterenko I, Wanningen S, Bagci-Onder T, Anderegg M, Shah K.Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas.PLoS ONE. 2012;7(11):e49219.
  • Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, Shen XN, Robertson CL, Dumur CI, Hylemon PB, Mukhopadhyay ND, Bhere D, Shah K, Ahmad R, Giashuddin S, Stafflinger J, Subler MA, Windle JJ, Fisher PB, Sarkar D.Astrocyte elevated gene-1 promotes hepatocarcinogenesis: Novel insights from a mouse model.Hepatology. 2012 Nov;56(5):1782-91.
  • van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen En Henegouwen PM, Shah K.Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16642-7.
  • Hingtgen S, Kasmieh R, Elbayly E, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Hall D, Kozakov D, Vajda S, Fisher PB, Shah K.A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy.PLoS ONE. 2012;7(7):e40234.
  • Kauer TM, Figueiredo JL, Hingtgen S, Shah K.Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.Nat Neurosci. 2012 Feb;15(2):197-204.
  • Shah K.Mesenchymal stem cells engineered for cancer therapy.Adv Drug Deliv Rev. 2011 Jun 29.
  • Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K.A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.Cancer Res. 2011 Jan 1;71(1):154-63.
  • Shah K.In vivo imaging of the dynamics of different variants of EGFR in glioblastomas.Methods Mol Biol. 2011;680:153-64.
  • Shah K.Imaging fate of stem cells at a cellular resolution in the brains of mice.Methods Mol Biol. 2011;680:91-101.
  • van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K.Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.Oncogene. 2010 Jun 3;29(22):3185-95.
  • Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P.Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma.Mol Ther. 2010 Jun;18(6):1130-42.
  • Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K.Determining Multiple Aspects of Stem Cell-Based Therapies Using Novel Diagnostic and Therapeutic Multifunctional Molecules.Stem Cells. 2010 Apr;28(4):832-41.
  • Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D.Molecular mechanism of chemoresistance by astrocyte elevated gene-1.Cancer Res. 2010 Apr 15;70(8):3249-58.
  • Piccirillo SG, Binda E, Fiocco R, Vescovi AL, Shah K.Brain cancer stem cells.J Mol Med. 2009 Nov;87(11):1087-95. Review.
  • Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, Dash R, Yacoub A, Fuller CE, Shah K, Dent P, Bruce JN, Fisher PB.Astrocyte elevated gene-1: a novel target for human glioma therapy.Mol Cancer Ther. 2010 Jan;9(1):79-88.
  • Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D.Identification of genes conferring resistance to 5-fluorouracil.Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12938-43.
  • Kumar AT, Chung E, Raymond SB, van de Water JA, Shah K, Fukumura D, Jain RK, Bacskai BJ, Boas DA.Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast.Opt Lett. 2009 Jul 1;34(13):2066-8.
  • Wakimoto H,Kesari S,Farrell CJ,Curry WT Jr,Zaupa C,Aghi M,Kuroda T,Stemmer-Rachamimov A,Shah K,Liu TC,Jeyaretna DS,Debasitis J,Pruszak J,Martuza RL,Rabkin SD.Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res. 2009 Apr 15;69(8):3472-81.
  • Shah K.Imaging neural stem cell fate in mouse model of glioma.Curr Protoc Stem Cell Biol. 2009 Mar;Chapter 5:Unit 5A.1.
  • Sasportas LS,Kasmieh R,Wakimoto H,Hingtgen S,van de Water JA,Mohapatra G,Figueiredo JL,Martuza RL,Weissleder R,Shah K.Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7.
  • Deliolanis NC,Kasmieh R,Wurdinger T,Tannous BA,Shah K,Ntziachristos V.Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications.J Biomed Opt. 2008 Jul-Aug;13(4):044008.
  • Hingtgen S,Ren X,Terwilliger E,Classon M,Weissleder R,Shah K.Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.Mol Cancer Ther. 2008 Nov;7(11):3575-85.
  • Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel DT, Grant S.Searching for a cure: Gene therapy for glioblastoma.Cancer Biol Ther. 2008 Sep;7(9):1335-40. Review.
  • Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P.MDA-7/IL-24 Plus Radiation Enhance Survival in Animals with Intracranial Primary Human GBM Tumors.Cancer Biol Ther. 2008 Jun;7(6):917-33.
  • Yip S, Shah K.Stem-cell based therapies for brain tumors.Curr Opin Mol Ther. 2008 Aug;10(4):334-42. Review.
  • Regan MM, Brick AJ, Choueiri TK, Clement JM, Kwabi C, Shah K, Amato A, McDermott DF, Atkins MB, Signoretti S.Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy.J Clin Oncol..
  • Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman J, Long AM, Moriguchi J, O'Connor A, Potashman MH, Reese M, Rex K, Siegmund A, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Bellon SF.Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase.J Med Chem. 2008 May 22;51(10):2879-82.
  • Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R.Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model.J Neurosci. 2008 Apr 23;28(17):4406-13.
  • Corsten MF, Shah K.Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare.Lancet Oncol. 2008 Apr;9(4):376-84. Review.
  • Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K.MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.Cancer Res. 2007 Oct 1;67(19):8994-9000.
  • Hink MA, Shah K, Russinova E, de Vries SC, Visser AJ.Fluorescence fluctuation analysis of Arabidopsis thaliana somatic embryogenesis receptor-like kinase and brassinosteroid insensitive 1 receptor oligomerization.Biophys J. 2008 Feb 1;94(3):1052-62.
  • Arwert E, Hingtgen S, Figueiredo JL, Bergquist H, Mahmood U, Weissleder R, Shah K.Visualizing the Dynamics of EGFR Activity and Antiglioma Therapies In vivo.Cancer Res. 2007 Aug 1;67(15):7335-42.
  • Minami Y, Shimamura T, Shah K, Laframboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK.The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Oncogene. 2007 Jul 26;26(34):5023-7.
  • Kock N, Kasmieh R, Weissleder R, Shah K.Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.Neoplasia. 2007 May;9(5):435-42.
  • Shah K, Breakefield XO.HSV Amplicon Vectors for Cancer Therapy.Curr Gene Ther. 2006 Jun;6(3):361-70. Review.
  • Shah K, Tung CH, Breakefield XO, Weissleder R.In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.Mol Ther. 2005 Jun;11(6):926-31.
  • Shah K.Current advances in molecular imaging of gene and cell therapy for cancer.Cancer Biol Ther. 2005 May;4(5):518-23.
  • Shah K, Weissleder R.Molecular optical imaging: applications leading to the development of present day therapeutics.NeuroRx. 2005 Apr;2(2):215-25.
  • Shah K, Hsich G, Breakefield XO.Neural precursor cells and their role in neuro-oncology.Dev Neurosci. 2004 Mar-Aug;26(2-4):118-30.
  • Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO.Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.Ann Neurol. 2005 Jan;57(1):34-41.
  • Shah K, Jacobs A, Breakefield XO, Weissleder R.Molecular imaging of gene therapy for cancer.Gene Ther. 2004 Aug;11(15):1175-87. Review.
  • Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH.A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe.Neoplasia. 2004 Mar-Apr;6(2):95-105.
  • Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO.Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy.Cancer Res. 2004 May 1;64(9):3236-42.
  • Kim DE, Schellingerhout D, Ishii K, Shah K, Weissleder R.Imaging of stem cell recruitment to ischemic infarcts in a murine model.Stroke. 2004 Apr;35(4):952-7.
  • Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R.In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas.Cancer Res. 2004 Jan 1;64(1):273-8.
  • Shah K, Tang Y, Breakefield X, Weissleder R.Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.Oncogene. 2003 Oct 9;22(44):6865-72.
  • Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R.In vivo tracking of neural progenitor cell migration to glioblastomas.Hum Gene Ther. 2003 Sep 1;14(13):1247-54.